logo_actinium

About the Company

Actinium Pharmaceuticals (NYSE: ATNM) is an oncology-focused company developing cancer treatments using monoclonal antibodies tethered to radioactive isotopes for the targeted delivery of radiation. The lead clinical program, Iomab-B™, is expected to enter a pivotal Phase III trial in mid-2015 for bone marrow conditioning in acute myeloid leukemia (AML) patients. Actinium is developing next-generation products using more powerful radioisotopes that emit alpha particles and has a full pipeline of candidates. Actimab-A has orphan drug designation in the US and is currently in a Phase I/II trial for newly diagnosed AML.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research